| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PF-543 | CTRPv2 | pan-cancer | AAC | 0.037 | 0.3 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | -0.032 | 0.3 |
| mRNA | BRD-A02303741 | CTRPv2 | pan-cancer | AAC | -0.038 | 0.3 |
| mRNA | CCT036477 | CTRPv2 | pan-cancer | AAC | -0.033 | 0.3 |
| mRNA | KIN001-270 | GDSC1000 | pan-cancer | AAC | 0.032 | 0.3 |
| mRNA | HG-5-88-01 | GDSC1000 | pan-cancer | AAC | 0.043 | 0.3 |
| mRNA | Tamoxifen | GDSC1000 | pan-cancer | AAC | 0.031 | 0.3 |
| mRNA | MP470 | GDSC1000 | pan-cancer | AAC | 0.031 | 0.3 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.031 | 0.3 |
| mRNA | ifosfamide | CTRPv2 | pan-cancer | AAC | -0.053 | 0.3 |